NCT Number: NCT02492412
Efficacy and Safety of HE10 for Dry Eye Syndrome
The purpose of this study is to evaluate the efficacy and safety of HE10 eye drop for the patients with moderate to severe dry eye syndrome.
Looking for future studies?
Notify MeKey information
Age range
21 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
About this study
This study is to compare the efficacy and safety of HE10 and Restasis for patients with moderate to severe dry eye syndrome in multi-center, double-blind, randomized, active comparator-controlled, parallel design, non-inferiority Phase III clinical trial.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Corneal staining score of ≥2(Oxford grade)
- Schirmer test score (without anesthesia) < 10 mm/5 min in either eye
- Tear break-up time is 10 seconds or less
- Screening both eyes, the corrected visual acuity is 0.2 or more
Exclusion criteria
- Current or recent patients used dry eye syndrome medications (topical or systemic) that may affect the status
- The patients with systemic or ocular disorders affected the test result
- Being treated with systemic steroid
- History of eyeball surgical operation within 3 months of screening visit
- Wearing contact lenses within 2 weeks of screening visit
- Be a use or used punctual plug within 1 month of screening vist
- Use of cyclosporine eye drop within 3 weeks
- Pregnancy or Breastfeeding
- Intraocular pressure > 25 mmHg
- Abnormal eyelid function : Disorders of the eyelids or eyelashes
Treatment and study plan
Restasis
DrugOther names: 0.05% cyclosporine
Primary outcomes
-
Corneal staining Test to assess eye dryness
Time frame: 12 weeks
Change from baseline in eye dryness at 12 weeks
Sponsors and collaborators
Lead sponsor
Huons Co., Ltd.
Industry
Registry information
Official study title
Multi-center, Randomized, Double-blind, Active Comparator- Controlled, Parallel Study Evaluating the Efficacy and Safety of HE10 in Subjects With Dry Eye Syndrome
Important dates
- Study start
- 2013
- Primary completion
- 2014
- Study completion
- 2014
- First posted
- Jul 8, 2015
- Registry last updated
- Jul 8, 2015
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment
NCT04343287
Dry Eye Syndrome, Dry Eye Syndromes
Newport Beach, California, United States
View Trial DetailsSafety and Efficacy of BRM421 for Dry Eye Syndrome
NCT03066219
Dry Eye Syndrome, Dry Eye Syndromes
Lewiston, Maine, United States
View Trial DetailsPerformance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome.
NCT06375499
Dry Eye Syndrome, Dry Eye Syndromes
Prague, Czechia
View Trial DetailsThe Effect of a New Emulsion in Dry Eye Patients on Tear Layer Aberrometry, Contrast Sensitivity, and Reading Ability
NCT01013077
Dry Eye Syndrome, Dry Eye Syndromes
Fullerton, California, United States
View Trial Details